1.Department of Thoracic Surgery, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830054, China;
2.Institute of Clinical Medicine, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830054, China
Abstract：Objective To study the TP53 gene deletion and p53 protein expression level in Uygur′s esophageal carcinoma, and its correlation with prognosis of Uygur esophageal cancer patients. Methods Sixty-seven cases of Uygur esophageal squamous cell carcinoma treated by radical resection from December 2009 to June 2013 in Department of Thoracic Surgery, the First Affiliated Hospital of Xinjiang Medical University were selected. TP53 gene deletion and p53 protein expression was detected respectively by fluorescence in situ hybridization and immuno-histo-chemistry methods. The relationship of TP53 gene deletion and p53 protein expression with clinicopathological factors and postoperative survival rate was analyzed. Results In the highly differentiated group, the deletion rate of TP53 gene was 15.00%, which of moderate and poorly differentiation group was 40.43%, the difference was statistically significant (P ＜ 0.05). There was no significant difference of the deletion rate of TP53 gene in different tumor invasion depth and lymph node metastasis status (P ＞ 0.05). There was no significant difference of the degree of p53 protein expression in different degrees of tumor differentiation, tumor invasion depth and lymph node metastatis status (P ＞ 0.05). Conclusion There is a certain correlation between TP53 gene deletion and the differentiation degree of esophageal carcinoma tumor, but the relationship with the survival has not been determined. The TP53 gene deletion and p53 protein expression level cannot be seen as the prognostic biomarkers of Uygur patients with esophageal cancer. Therefore, larger sample capacity is needed for in-depth exploration and determination.
[1] 赫捷，邵康.中国食管癌流行病学现状、诊疗现状及未来对策[J].中国癌症杂志，2011，21（7）：501-504.
[2] Lu XM，Zhang YM，Lin RY，et al. Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1，GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang，China [J]. World J Gastroenterol，2005，11（24）：3651-3654.
[3] 居来提·艾尼瓦尔，李德生，张力为，等.新疆2005～2008年伊犁地区食管癌患病情况调查研究[J].新疆医学，2011， 41（10）：112-114.
[4] Ko LJ，Prives C. p53：Puzzle and paradigm [J]. Genes Dev，1996，10（9）：1054-1072.
[5] Schmale H，Bamberger C. A novel protein with strong homology to the tumor suppressor p53 [J]. Oncogene，1997， 15（11）：1363-1367.
[6] Hamelin R，Fléjou JF，Muzeau F，et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus [J]. Gastroenterology，1994，107（4）：1012-1018.
[7] Brankley SM，Fritcher EG，Smyrk TC. Fluorescence in situhybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma [J]. Hum Pathol，2012，43（2）：172-179.
[8] LI Weijiang，Duan Jinxia. Detecting of p53 gene heterozygosity loss in esophageal carcinoma tissues [J]. Journal of Zhengzhou University（Medical Sciences），2004，39（3）：499-501.
[9] Rice TW，Blackstone EH，Rusch VW. 7th Edition of the AJCC Cancer Staging Manual：Esophagus and Esophagogastric Junction [J]. Ann Surg Oncol，2010，17（7）：1721-1724.
[10] Hollstein MC，Metcalf RA，Welsh JA，et al. Frequent mutation of the p53 gene in human esophageal cancer [J]. Proc Natl Acad Sci U S A，1990，87（24）：9958-9961.
[11] Fagundes RB，Melo CR，Pütten ACK，et al. p53 immunoexpres-sion：an aid to conventional methods in the screening of precursor lesions of squamous esophageal cancer in patients at high-risk? [J]. Cancer Detect Prev，2005，29（3）：227-232.
[12] Ando N，Kato H，Igaki H，et al. A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus（JCOG9907）[J]. Ann Surg Oncol，2012，19（1）：68-74.
[13] O'Connor PM，Jackman J，Jondle D，et al. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines [J]. Cancer Research，1993，53（20）：4776-4780.
[14] Gao H，Wang LD，Zhou Q，et al. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan，China [J]. Cancer Res，1994，54（16）：4342-4346.
[15] 陈新，平育敏，白世祥，等. p16和p53在食管鳞状细胞癌中的表达及意义[J].实用肿瘤杂志，2004，19（1）：23-27.
[16] Reid BJ，Prevo LJ，Galipeau PC，et al. Predictors of progression in Barrett's esophagus Ⅱ：baseline 17p（p53）loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression [J]. Am J Gastro，2001，96（10）：2839-2848.
[17] Coggi G，Bosari S，Roncalli M，et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma [J]. Cancer，1997，79（3）：425-432.
[18] Sarbia M，Porschen R，Borchard F，et al. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus [J]. Cancer，1994，74（8）：2218-2223.
[19] Inada S，Koto T，Futami K，et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study（p53，E-cadherin，epidermal growth factor receptor）[J]. Surgery Today，1999，29（6）：493-503.
[20] 杨宣琴，王全红，李光.食管鳞状细胞癌p53基因杂合性缺失和基因突变的相关研究[J].肿瘤研究与临床，2006，18（2）：92-94.
[21] 廖琼，郭玉萍，杨素琼，等.食管鳞状细胞癌P53蛋白表达和基因突变与预后的关系[J].四川医学，2004，25（1）：103-105.
[22] 陈旭峰，吕桂泉，曹巍，等.食管鳞状细胞癌中p53基因变异的临床意义及地域性差别[J].中华医学杂志，1999， 79（11）：841-843.
2018, Vol. 15 
京公网安备 11010502046598号